ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial | MicrobiomeTrials
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2025-07-28Est. Completion: 2027-07-30
Enrollment target: 50 participants
Locations
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Other microbiome trials you might be interested in
Recurrent GlioblastomaGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeRelapsed CancerRecurrent TumorGlioblastoma MultiformeRecurring GlioblastomaBrain and Central Nervous System TumorsGliomaGlioblastomasGrade IV AstrocytomaGBMRecurrent Glioma (Glioblastoma Multiforme)High Grade GliomaGlioma, MalignantBrain Cancer
Background:
Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. B…
Bethesda, United StatesEst. completion Dec 31, 2030